Peanut Allergy Clinical Trial
— IMMULITE 2000Official title:
The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy
Verified date | October 2020 |
Source | National Jewish Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Food allergy is on the rise within the pediatric population. Having food allergy can cause medical, nutritional and psychological issues in those who suffer with it. Although making the appropriate diagnosis of food allergy is very important, properly diagnosing food allergy has been a challenge. Skin prick testing and food-specific IgE testing of the blood can give positive results that are false. Currently, Oral Food Challenges are the best way to diagnose a food allergy. Unfortunately, Oral Food Challenges are time consuming and may not be readily available to suspected food allergy sufferers. This study is designed to examine the effectiveness of an allergy-detecting blood test called IMMULITE 2000 manufactured by the study sponsor, Siemens.
Status | Completed |
Enrollment | 102 |
Est. completion date | March 29, 2017 |
Est. primary completion date | March 29, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 3 Years to 21 Years |
Eligibility | Inclusion Criteria: - Age 3 to 21 years of either sex and any race - Physician-diagnosed food allergy or convincing clinical history of food allergy to milk, egg, and/or peanut AND a Skin prick test positive to milk, egg, and/or peanut (diameter of wheal > 3 mm or greater than negative control) orOR a detectable serum food-specific IgE level (ImmunoCAP and/or IMMULITE > 0.35 kUA/L) to milk, egg, and/or peanut - If no history of clinical reactivity to milk, egg, or peanut, then a positive skin prick test to milk, egg, and/or peanut (diameter of wheal > 3 mm or greater than negative control) OR a detectable serum food-specific IgE level within the previous 4 months to milk, egg, and/or peanut - Written informed consent from parent/guardian and assent (when age appropriate). - Willingness to submit specimen for laboratory serum IgE testing Exclusion Criteria: - Inability to discontinue antihistamines for skin prick testing and OFCs - Current allergy to placebo ingredient (oat flour) OR reaction to any dose of placebo at the qualifying OFC - FEV1 value <80% predicted OR any clinical features of moderate or severe persistent asthma, as defined by the 2007 NHLBI guidelines table for classifying asthma baseline severity (Step 3 or above), at the time of entry into the study - Use of , and >high medium daily doses of inhaled corticosteroids, as defined by the 2007 NHLBI guidelines inhaled corticosteroid dosing table (500500 µg/day fluticasone or equivalents for an adult) or a long acting beta-agonist (LABA) to control asthma. - Asthma requiring either: > 1 hospitalization in the past year for asthma or > 1 ER visit in the past 6 months for asthma - History of intubation due to allergies or asthma - Use of steroid medications (IV, IM or oral) for asthma in the following manners: - history of daily oral steroid dosing for >1 month during the past year or - burst or steroid course/burst in the past 3 months or - >2 burst oral steroid courses/bursts in the past year - History of intubation due to allergies or asthma - Life-threatening allergic reaction (e.gi.e., respiratory compromise, hypoxia, hypotension, use of epinephrine) to study food(s) (e.g., milk, egg, and/or peanut) within last 1 year - Diagnosis of active eosinophilic gastrointestinal disease in the past year - Severe or poorly controlled atopic dermatitis, as assessed by a three-item severity (TIS) score of 6 or greater (see Appendix I) - Use of omalizumab or other non-traditional forms of allergen immunotherapy (e.g., oral or sublingual), immunomodulatory therapy (not including corticosteroids), or biologic therapy within the past year - Uncontrolled hypertension - Any use of ß-blockers (oral), angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARB) or calcium channel blockers - Other significant medical conditions (e.g., liver, gastrointestinal, kidney, cardiovascular, pulmonary disease, or blood disorders), which, in the opinion of the Investigator, make the subject unsuitable for induction of food reactions - Pregnancy |
Country | Name | City | State |
---|---|---|---|
United States | National Jewish Health | Denver | Colorado |
Lead Sponsor | Collaborator |
---|---|
National Jewish Health |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Relationship between food specific IgEs | To determine the relationship between food-specific IgE to whole proteins of milk, egg, and peanut using the IMMULITE 2000 assay and OFC outcomes. | approximately 2 weeks | |
Secondary | Logisitic regression analyses on data | To compare the results of logistic regression analyses using the IMMULITE 2000 assay and food challenge outcome data to data obtained in parallel using the ImmunoCAP assay for food-specific IgE antibodies. | approximately 2 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05667610 -
Immune-supportive Diet and Gut Permeability in Allergic Children
|
N/A | |
Recruiting |
NCT05440643 -
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
|
Phase 1 | |
Terminated |
NCT03849079 -
Validation of the HYPONUT Product
|
N/A | |
Completed |
NCT02979600 -
Clinical and Biological Efficacy of Peanut Oral Immunotherapy
|
N/A | |
Completed |
NCT01955109 -
Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children
|
Phase 2 | |
Recruiting |
NCT04415593 -
High and Low Dose Oral Peanut Immunotherapy - Comparison of Efficacy and Safety
|
N/A | |
Active, not recruiting |
NCT04511494 -
Oral Immunotherapy for Young Children With Peanut Allergy - Small Children OIT
|
N/A | |
Active, not recruiting |
NCT04887441 -
Allergology: Information, Data and Knowledge Organization
|
||
Active, not recruiting |
NCT04881773 -
Oral Low Doses Tolerance INduction Study for Peanuts
|
||
Completed |
NCT03682770 -
Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
|
Phase 2 | |
Terminated |
NCT03703791 -
Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents
|
Phase 3 | |
Completed |
NCT02916446 -
Safety Study of Viaskin Peanut to Treat Peanut Allergy
|
Phase 3 | |
Active, not recruiting |
NCT02402231 -
Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy
|
Phase 2 | |
Completed |
NCT03337542 -
AR101 Real-World Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT05476497 -
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
|
Phase 1 | |
Completed |
NCT03648320 -
The Grown Up Peanut Immunotherapy Study
|
N/A | |
Completed |
NCT03292484 -
Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)
|
Phase 3 | |
Completed |
NCT03852342 -
Reactive Doses and Times During Oral Food Challenge to Peanut
|
||
Recruiting |
NCT05138757 -
Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy
|
Phase 1/Phase 2 | |
Completed |
NCT03352726 -
A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects
|
Phase 1 |